Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$138.21
+0.1%
$132.54
$99.71
$141.23
$240.18B0.736.10 million shs1.42 million shs
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$23.27
-0.2%
$21.50
$12.21
$41.31
$681.47M-0.26633,768 shs73,816 shs
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
$0.80
+2.1%
$0.87
$0.68
$4.45
$529.73M0.59618,198 shs60,346 shs
Evotec AG stock logo
EVO
Evotec
$4.15
+1.6%
$4.07
$2.84
$5.64
$1.48B1.66134,052 shs18,837 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+3.65%+4.50%+5.19%+9.23%+31.18%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+2.19%-2.10%+14.09%+28.20%-3.04%
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
+0.26%-5.44%-8.78%-11.09%-81.01%
Evotec AG stock logo
EVO
Evotec
+7.09%+1.75%-13.74%+19.65%-11.30%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9574 of 5 stars
2.45.04.24.53.62.52.5
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
1.3939 of 5 stars
3.40.00.00.01.11.70.6
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
2.1242 of 5 stars
3.52.00.00.01.70.01.3
Evotec AG stock logo
EVO
Evotec
1.7079 of 5 stars
3.24.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.613.19% Upside
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$42.3882.14% Upside
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
3.00
Buy$6.25682.72% Upside
Evotec AG stock logo
EVO
Evotec
2.40
Hold$5.9343.14% Upside

Current Analyst Ratings Breakdown

Latest EVO, ABT, ANAB, and CURLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/15/2025
Evotec AG stock logo
EVO
Evotec
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/6/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $54.00
5/1/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
4/24/2025
Evotec AG stock logo
EVO
Evotec
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Hold
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.68$6.83 per share20.24$27.62 per share5.00
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M7.49N/AN/A$2.33 per share9.98
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
$1.34B0.39$0.21 per share3.81$1.51 per share0.53
Evotec AG stock logo
EVO
Evotec
$862.40M1.71N/AN/A$2.91 per share1.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.9124.122.5331.89%19.01%10.82%7/17/2025 (Estimated)
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
-$215.42M-$0.31N/AN/AN/A-17.37%-14.12%-4.40%N/A
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-26.34%-21.51%-10.54%8/13/2025 (Estimated)

Latest EVO, ABT, ANAB, and CURLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
5/8/2025Q1 2025
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
-$0.07-$0.07N/A-$0.08N/AN/A
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.71%N/A30.61%54 Years
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A

Latest EVO, ABT, ANAB, and CURLF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.25
8.25
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
1.08
1.41
0.70
Evotec AG stock logo
EVO
Evotec
0.46
2.03
1.93

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
0.03%
Evotec AG stock logo
EVO
Evotec
5.81%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
N/A
Evotec AG stock logo
EVO
Evotec
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million19.54 millionOptionable
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
5,519663.41 millionN/ANot Optionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 millionN/ANot Optionable

Recent News About These Companies

Evotec AG stock logo
Evotec (NASDAQ:EVO) Shares Gap Down - Here's Why
Evotec AG stock logo
Evotec (NASDAQ:EVO) Shares Gap Up - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$138.21 +0.13 (+0.09%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$23.26 -0.06 (-0.24%)
As of 11:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Curaleaf stock logo

Curaleaf OTCMKTS:CURLF

$0.80 +0.02 (+2.11%)
As of 11:16 AM Eastern

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

Evotec stock logo

Evotec NASDAQ:EVO

$4.14 +0.07 (+1.59%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.